It's time to rethink nerve repair! AxoGen (NASDAQ: AXGN) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. People suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. Damage may cause loss of function and feeling. AxoGen is bringing the science of nerve repair to life with its Avance® Nerve Graft which AxoGen believes is the first and only commercially available allograft for bridging nerve discontinuities, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector that protects nerves during the healing process.
Type
Public
HQ
Alachua, US
Founded
2002
Size (employees)
114 (est)+41%
AxoGen was founded in 2002 and is headquartered in Alachua, US

Key People at AxoGen

Karen Zaderej

Karen Zaderej

CEO
Gregory G. Freitag

Gregory G. Freitag

CFO&Director
Jill F. Schiaparelli

Jill F. Schiaparelli

Senior Vice President

AxoGen Office Locations

AxoGen has office in Alachua
Alachua, US

AxoGen Metrics

AxoGen Summary

Market capitalization

$350 M

Closing share price

$10.6
AxoGen's current market capitalization is $350 M.

AxoGen Financials

AxoGen's revenue is $27.3 M in FY, 2015 which is 62.52% increase from the previous period.
FY, 2015FY, 2014FY, 2013

Revenue

$27.3 M$16.8 M$10.9 M

Revenue growth, %

62.5%53.6%

Gross profit

$22.5 M$13.4 M$8.51 M

Operating income

$-9.27 M$-9.8 M$-9.59 M

Operating expense total

$26.9 M$19.7 M$15.7 M

Net Income

$-13.4 M$-17.7 M$-14.6 M

Operating cash flow

$17.7 M$-11.9 M$6.16 M

AxoGen Market Value History

AxoGen Online Presence

AxoGen Company Life

You may also be interested in